相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Silke Gillessena et al.
EUROPEAN UROLOGY (2020)
A novel approach for propensity score matching and stratification for multiple treatments: Application to an electronic health record-derived study
Derek W. Brown et al.
STATISTICS IN MEDICINE (2020)
Impact of metastatic lymph node burden on survival in patients with mHSPC from the docetaxel comparison of the STAMPEDE trial
A. M. Haran et al.
ANNALS OF ONCOLOGY (2020)
Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer
Adnan Ali et al.
BJU INTERNATIONAL (2019)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N. W. Clarke et al.
ANNALS OF ONCOLOGY (2019)
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Paul J. Roach et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al.
EUROPEAN UROLOGY (2018)
Seven- Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Lauren C. Harshman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2015)
Survival with Newly Diagnosed Metastatic Prostate Cancer in the Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James et al.
EUROPEAN UROLOGY (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
Catherine M. Tangen et al.
JOURNAL OF UROLOGY (2012)
Choosing the relative survival method for cancer survival estimation
Timo Hakulinen et al.
EUROPEAN JOURNAL OF CANCER (2011)
Multiple imputation of discrete and continuous data by fully conditional specification
Stef van Buuren
STATISTICAL METHODS IN MEDICAL RESEARCH (2007)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial)
DP Dearnaley et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
分享论文
